In total, between 20.0% and 23.3% of the tumours are Rbpositive/p16negative, Rbpositive/CDK4positive, or Rbpositive/CDK6high, which corresponds to the group of patients that might benefit from CDK4/CDK6 inhibitor treatment. This evidence concerns the gene CDK6 and neoplasm.